Trevi Therapeutics Stock Probability of Future Stock Price Finishing Over 6.88

TRVI Stock  USD 2.91  0.18  6.59%   
Trevi Therapeutics' future price is the expected price of Trevi Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Trevi Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Trevi Therapeutics Backtesting, Trevi Therapeutics Valuation, Trevi Therapeutics Correlation, Trevi Therapeutics Hype Analysis, Trevi Therapeutics Volatility, Trevi Therapeutics History as well as Trevi Therapeutics Performance.
For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.
  
As of now, Trevi Therapeutics' Price Book Value Ratio is increasing as compared to previous years. The Trevi Therapeutics' current Price To Book Ratio is estimated to increase to 1.69, while Price Earnings Ratio is projected to decrease to (4.79). Please specify Trevi Therapeutics' target price for which you would like Trevi Therapeutics odds to be computed.

Trevi Therapeutics Target Price Odds to finish over 6.88

The tendency of Trevi Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move over $ 6.88  or more in 90 days
 2.91 90 days 6.88 
close to zero percent
Based on a normal probability distribution, the odds of Trevi Therapeutics to move over $ 6.88  or more in 90 days from now is close to zero percent (This Trevi Therapeutics probability density function shows the probability of Trevi Stock to fall within a particular range of prices over 90 days) . Probability of Trevi Therapeutics price to stay between its current price of $ 2.91  and $ 6.88  at the end of the 90-day period is about 84.13 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.89 . This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Trevi Therapeutics will likely underperform. Additionally Trevi Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Trevi Therapeutics Price Density   
       Price  

Predictive Modules for Trevi Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Trevi Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Trevi Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.152.926.86
Details
Intrinsic
Valuation
LowRealHigh
0.203.927.86
Details
Naive
Forecast
LowNextHigh
0.062.916.85
Details
9 Analysts
Consensus
LowTargetHigh
6.677.338.14
Details

Trevi Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Trevi Therapeutics is not an exception. The market had few large corrections towards the Trevi Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Trevi Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Trevi Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.08
β
Beta against Dow Jones1.89
σ
Overall volatility
0.18
Ir
Information ratio 0.01

Trevi Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Trevi Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Trevi Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Trevi Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0.
Trevi Therapeutics currently holds about 77.86 M in cash with (31.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Trevi Therapeutics has a frail financial position based on the latest SEC disclosures
Over 81.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc.

Trevi Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Trevi Stock often depends not only on the future outlook of the current and potential Trevi Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Trevi Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding99 M
Cash And Short Term Investments83 M

Trevi Therapeutics Technical Analysis

Trevi Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Trevi Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Trevi Therapeutics. In general, you should focus on analyzing Trevi Stock price patterns and their correlations with different microeconomic environments and drivers.

Trevi Therapeutics Predictive Forecast Models

Trevi Therapeutics' time-series forecasting models is one of many Trevi Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Trevi Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Trevi Therapeutics

Checking the ongoing alerts about Trevi Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Trevi Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Trevi Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (29.07 M) with profit before overhead, payroll, taxes, and interest of 0.
Trevi Therapeutics currently holds about 77.86 M in cash with (31.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Trevi Therapeutics has a frail financial position based on the latest SEC disclosures
Over 81.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc.
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.44)
Return On Assets
(0.37)
Return On Equity
(0.60)
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.